Tachykinin Receptor Antagonists: Silencing Neuropeptides with a Role in the Disturbed Gut

Pathophysiology of the Enteric Nervous System: A Basis for Understanding Functional Diseases

Volumn , Issue , 2008, Pages 212-227

  Holzer, Peter ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Human endokinin d; Neurokinin; Neuropeptides; Non vertebrate species; Tachykinin receptors

Indexed keywords

EID: 84992751349     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470760307.ch17     Document Type: Chapter

References (79)

1. Pernow B. Substance P. Pharmacol Rev 1983; 35: 85-141.
2. Chang MM, Leeman SE. Isolation of a sialogogic peptide from bovine hypothalamic tissue and its characterization as substance P. J Biol Chem 1970; 245: 4784-90.
3. Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V. The tachykinin peptide family. Pharmacol Rev 2002; 54: 285-322.
4. Maggio JE. Tachykinins. Annu Rev Neurosci 1988; 11: 13-28.
5. Nakanishi S. Mammalian tachykinin receptors. Annu Rev Neurosci 1991; 14: 123-36.
6. Maggi CA. The mammalian tachykinin receptors. Gen Pharmacol 1995; 26: 911-44.
7. Andrews PLR, Rudd JA. The role of tachykinins and the tachykinin NKt receptor in nausea and emesis. In: Holzer P, ed. Tachykinins. Handbook of Experimental Pharmacology, Vol. 164. Berlin: Springer, 2004: 359-440.
8. Patacchini R, Lecci A, Holzer P, Maggi CA. Newly discovered tachykinins raise new questions about their peripheral roles and the tachykinin nomenclature. Trends Pharmacol Sei 2004; 25: 1-3.
9. Maggi CA, Schwartz TW. The dual nature of the tachykinin NK, receptor. Trends Pharmacol Sei 1997; 18: 351-4.
10. Holzer P, Holzer-Petsche U. Tachykinins in the gut. Part I. Expression, release and motor function. Pharmacol Ther 1997; 73: 173-217.
11. Holzer P. Role of tachykinins in the gastrointestinal tract. In: Holzer P, ed. Tachykinins. Handbook of Experimental Pharmacology, Vol. 164. Berlin: Springer, 2004: 511-58.
12. Furness JB. Types of neurons in the enteric nervous system. JAuton Nerv Syst 2000; 81: 87-96.
13. Brookes SJH. Classes of enteric nerve cells in the guinea-pig small intestine. Anat Ree 2001; 262: 58-70.
14. Schemann M, Reiche D, Michel K. Enteric pathways in the stomach. Anat Ree 2001; 262: 47-57.
15. Holzer P, Holzer-Petsche U. Tachykinins in the gut. Part II. Roles in neural excitation, secretion and inflammation. Pharmacol Ther 1997; 73: 219-63.
16. Maggi CA. Principles of tachykininergic co-transmission in the peripheral and enteric nervous system. Regul Pept 2000; 93: 53-64.
17. Furness JB, Sanger GJ. Intrinsic nerve circuits of the gastrointestinal tract: identification of drug targets. Cwrr Opin Pharmacol 2002; 2: 612-22.
18. Alex G, Clerc N, Kunze WA, Furness JB. Responses of myenteric S neurones to low frequency stimulation of their synaptic inputs. Neuroscience 2002; 110: 361-73.
19. Thornton PD, Bornstein JC. Slow excitatory synaptic potentials evoked by distension in myenteric descending interneurones of guinea-pig ileum. J Physiol (Lond) 2002; 539: 589-602.
20. Tonini M, De Ponti F, Frigo G, Crema F. Pharmacology of the enteric nervous system. In: Brookes S, Costa M, eds. Innervation of the Gastrointestinal Tract. London: Taylor & Francis, 2002:213-94.
21. Lecci A, Santicioli P, Maggi CA. Pharmacology of transmission to gastrointestinal muscle. Curr Opin Pharmacol 2002; 2: 630-41.
22. Patacchini R, Maggi CA, Holzer P. Tachykinin autoreceptors in the gut. Trends Pharmacol Sci 2002; 21: 166.
23. Huizinga JD, Thuneberg L, Vanderwinden JM, Rumessen Jf. Interstitial cells of Cajal as targets for pharmacological intervention in gastrointestinal motor disorders. Trends Pharmacol Sci 1997; 18: 393-403.
24. 2 receptors mediate neurally induced contraction of human sigmoid circular smooth muscle. Gastroenterology 2000; 119: 51-61.
25. Lordal M, Theodorsson E, Hellstrom PM. Tachykinins influence interdigestive rhythm and contractile strength of human small intestine. Dig Dis Sci 1997; 42: 1940-9.
26. Lordal M, Navalesi G, Theodorsson E, Maggi CA, Hellstrom PM. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol 2001; 134: 215-23.
27. Lecci A, De Giorgio R, Bartho L et al. Tachykinin NKj receptor-mediated inhibitory responses in the guinea-pig small intestine. Neuropeptides 1999; 33: 91-7.
28. Holzer P, Schluet W, Maggi CA. Substance P stimulates and inhibits intestinal peristalsis via distinct receptors. J Pharmacol Exp Ther 1995; 274: 322-8.
29. Holzer P. Involvement of nitric oxide in the substance P-in-duced inhibition of intestinal peristalsis. Neuroreport 1997; 8: 2857-60.
30. Crema F, Moro E, Nardelli G, de Ponti F, Frigo G, Crema A. Role of tachykininergic and cholinergic pathways in modulating canine gastric tone and compliance in vivo. Pharmacol Res 2002; 45: 341-7.
31. Onori L, Aggio A, Taddei G et al. Peristalsis regulation by tachykinin NK, receptors in the rabbit isolated distal colon. Am J Physiol 2003; 285: G325-31.
32. Campos D, Pereira JR, Reinhardt RR et al. Prevention of cis-platin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexametha-sone or with dexamethasone alone. J Clin Oncol 2001; 19: 1759-67.
33. Goldstein DJ, Wang O, Gitter BD, Iyengar S. Dose-response study of the analgesic effect of lanepitant in patients with painful diabetic neuropathy. Clin Neuropharmacol 2001; 24: 16-22.
34. Holzer P, Maggi CA. Synergistic role of muscarinic acetylcholine and tachykinin NK-2 receptors in intestinal peristalsis. Naunyn Schmiedeberg's Arch Pharmacol 1994; 349: 194-201.
35. 2 receptor-mediated control of peristaltic propulsion in the guinea-pig small intestine in vitro.Neuropharmacology 1998; 37: 131-8.
36. Al-Saffar A, Hellstrom PM. Contractile responses to natural tachykinins and selective tachykinin analogs in normal and inflamed ileal and colonic muscle. Scand J Gastroenterol 2002; 36: 485-93.
37. Krysiak PS, Preiksaitis HG. Tachykinins contribute to nerve-mediated contractions in the human esophagus. Gastroenterology 2001; 120: 39-48.
38. Mitolo-Chieppa D, Mansi G, Nacci C et al. Idiopathic chronic constipation: tachykinins as cotransmitters in colonic contraction. Eur J Clin Invest 2001; 31: 349-55.
39. Tonini M, Spelta V, De Ponti F et al. Tachykinin-depen-dent and -independent components of peristalsis in the guinea pig isolated distal colon. Gastroenterology 2001; 120: 938-45.
40. Riegler M, Castagliuolo I, So PT et al. Effects of substance P on human colonic mucosa in vitro. Am J Physiol 1999; 276: G1473-83.
41. Moriarty D, Goldhill J, Selve N, O'Donoghue DP, Baird AW. Human colonic anti-secretory activity of the potent NKj antagonist, SR140333: assessment of potential anti-diarrhoeal activity in food allergy and inflammatory bowel disease. Br J Pharmacol 2001; 133: 1346-54.
42. Tough IR, Lewis CA, Fozard J, Cox HM. Dual and selective antagonism of neurokinin NK, and NK2 receptor-mediated responses in human colon mucosa. Naunyn-Schmiedeberg's Arch Pharmacol 2003; 367: 104-8.
43. Cooke HJ, Sidhu M, Wang YZ. Activation of 5-HT]p receptors on submucosal afferents subsequently triggers VIP neurons and chloride secretion in the guinea-pig colon. J Auton Nerv Syst 1997; 66: 105-10.
44. Frieling T, Dobreva G, Weber E et al. Different tachykinin receptors mediate chloride secretion in the distal colon through activation of submucosal neurones. Naunyn Schmiedeberg's Arch Pharmacol 1999; 359: 71-9.
45. Weber E, Neunlist M, Schemann M, Frieling T. Neural components of distension-evoked secretory responses in the guinea-pig distal colon. J Physiol (Lond) 2001; 536: 741-51.
46. Cooke HJ, Sidhu M, Fox P, Wang YZ, Zimmermann EM. Substance P as a mediator of colonic secretory reflexes. Am J Physiol 1997; 272: G238-5.
47. Pothoulakis C, Castagliuolo I, LaMont JT et al. CP-96,345, a substance P antagonist, inhibits rat intestinal responses to Clostridium difficile toxin A but not cholera toxin. Proc Natl Acad Sci USA 1994; 91: 947-51.
48. Schmidt PT, Lördal M, Gazelius B, Hellström PM. Tachykinins potently stimulate human small bowel blood flow: a laser Doppler flowmetry study in humans. Gut 2003; 52: 53-6.
49. Rydning A, Lyng O, Aase S, Grönbech JE. Substance P may attenuate gastric hyperemia by a mast cell-dependent mechanism in the damaged gastric mucosa. Am J Physiol 1999; 277: G1064-73.
50. Sturiale S, Barbara G, Qiu B et al. Neutral endopeptidase (EC 3.4.24.11) terminates colitis by degrading substance P. Proc Natl Acad Sci USA 1999; 96: 11653-8.
51. Maggi CA. The effects of tachykinins on inflammatory and immune cells. Regul Pept 1997; 70: 75-90.
52. Neunlist M, Aubert P, Toquet C et al. Changes in chemical coding of myenteric neurones in ulcerative colitis. Gut 2003; 52: 84-90.
53. Mantyh CR, Vigna SR, Bollinger RR, Mantyh PW, Maggio JE, Pappas TN. Differential expression of substance P receptors in patients with Crohn's disease and ulcerative colitis. Gastroenterology 1995; 109: 850-60.
54. GoodeT, O'Connell J, Anton P etal. Neurokinin-1 receptor-' expression in inflammatory bowel disease: molecular quantitation and localisation. Gut 2000; 47: 387-96.
55. Renzi D, Pellegrini B, Tonelli F, Surrenti C, Calabro A. Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine. Am J Pathol 2000; 157: 1511-22.
56. Mantyh CR, Maggio JE, Mantyh PW, Vigna SR, Pappas TN. Increased substance P receptor expression by blood vessels and lymphoid aggregates in Clostridium difficile-induced pseudomembranous colitis. Dig Dis Sci 1996; 41: 614-20.
57. Pothoulakis C, Castagliuolo I, Leeman SE et al. Substance P receptor expression in intestinal epithelium in Clostridium difficile toxin A enteritis in rats. Am J Physiol 1998; 275: G68-75.
58. de Wit R, Herrstedt J, Rapoport B et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy. J Clin Oncol 2003; 21:4105-11.
59. Menzies JR, McKee R, Corbett AD. Differential alterations in tachykinin NK2 receptors in isolated colonic circular smooth muscle in inflammatory bowel disease and idiopathic chronic constipation. Regul Pept 2001; 99: 151-6.
60. Stanton MP, Hengel PT, Southwell BR et al. Cholinergic transmission to colonic circular muscle of children with slow-transit constipation is unimpaired, but transmission via NK2 receptors is lacking. Neurogastroenterol Motil 2003; 15:669-78.
61. Castagliuolo I, Riegler M, Pasha A et al. Neurokinin-1 (NK-1) receptor is required in Clostridium difficile-induced enteritis. J Clin Invest 1998; 101: 1547-50.
62. Croci T, Landi M, Emonds-Alt X, Le Fur G, Maffrand JP, Manara L. Role of tachykinins in castor oil diarrhoea in rats. Br J Pharmacol 1997; 121: 375-80.
63. Mazelin L, Theodorou V, More J, Emonds-Alt X, Fioramon-ti J, Bueno L. Comparative effects of nonpeptide tachykinin receptor antagonists on experimental gut inflammation in rats and guinea-pigs. Life Sci 1998; 63: 293-304.
64. Turvill JL, Connor P, Farthing MJ. Neurokinin 1 and 2 receptors mediate cholera toxin secretion in rat jejunum. Gastroenterology 2000; 119: 1037-14.
65. Cutrufo C, Evangelista S, Cirillo R et al. Protective effect of the tachykinin NK, receptor antagonist nepadutant in acute rectocolitis induced by diluted acetic acid in guinea-pigs. Neuropeptides 2000; 34: 355-9.
66. Kirkwood KS, Bunnett NW, Maa J et al. Deletion of neutral endopeptidase exacerbates intestinal inflammation induced by Clostridium difficile toxin A. Am J Physiol 2001; 281: G544-51.
67. Wershil BK, Castagliuolo I, Pothoulakis C. Direct evidence of mast cell involvement in Clostridium difficile toxin A-induced enteritis in mice. Gastroenterology 1998; 114: 956-64.
68. Castagliuolo I, Keates AC, Qiu BS et al. Increased substance P responses in dorsal root ganglia and intestinal macrophages during Clostridium difficile toxin A enteritis in rats. Proc Natl Acad Sci USA 1997; 94:4788-93.
69. Metwali A, Blum AM, Ferraris L, Klein JS, Fiocchi C, Weinstock JV. Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide. J Neuroimmunol 1994; 52: 69-78.
70. Lecci A, Valenti C, Maggi CA. Tachykinin receptor antagonists in irritable bowel syndrome. Curr Opin Investig Drugs 2002; 3: 589-601.
71. Lee O-Y, Munakata J, Naliboff BD, Chang L, Mayer EA. A double blind parallel group pilot study of the effects of CJ-11,974 and placebo on perceptual and emotional responses to rectosigmoid distension in IBS patients. Gastroenterology 2000; 118: A846.
72. Laird JM, Olivar T, Roza C, De Felipe C, Hunt SP, Cervero F. Deficits in visceral pain and hyperalgesia of mice with a disruption of the tachykinin NK, receptor gene. Neuroscience 2000; 98: 345-52.
73. Kamp EH, Beck DR, Gebhart GF. Combinations of neurokinin receptor antagonists reduce visceral hyperalgesia. J Pharmacol Exp Ther 2001; 299: 105-13.
74. Julia V, Morteau O, Bueno L. Involvement of neurokinin 1 and 2 receptors in viscerosensitive response to rectal distension in rats. Gastroenterology 1994; 107: 94-102.
75. Julia V, Su X, Bueno L, Gebhart GF. Role of neurokinin 3 receptors on responses to colorectal distension in the rat: electrophysiological and behavioral studies. Gastroenterology 1999; 116: 1124-31.
76. Okano S, Ikeura Y, Inatomi N. Effects of tachykinin NK, receptor antagonists on the viscerosensory response caused by colorectal distension in rabbits. J Pharmacol Exp Ther 2002; 300: 925-31.
77. 2 receptors in the medullary transmission of vagal afferent input from the acid-threatened rat stomach. Pain 2001; 89: 147-57. 78.
78. Rupniak NMJ, Kramer MS. Discovery of the anti-depressant and anti-emetic efficacy of substance P receptor (NK,) antagonists. Trends Pharmacol Sci 1999; 20: 485-90.
79. Kramer MS, Winokur A, Kelsey J et al. Demonstration of the efficacy and safety of a novel substanceP (NKj) receptor antagonist in major depression. Neuropsychopharmacology 2004; 29: 385-92.